Glucosinolates as possible revertants of drug-resistance

Periodicum Biologorum

Volumn 104, Issue 4, 2002, Pages 475-479

  Durgo, Ksenija ^a   Osmak, Maja ^b   Garaj Vrhovac, Verica ^c   Čolić, Jasna Franekić ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b RUDER BO KOVI INSTITUTE   (Croatia)

^c INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; CAULIFLOWER EXTRACT; CISPLATIN; GLUCOSINOLATE; GLUTATHIONE; GLYCOPROTEIN P; PLANT EXTRACT; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CANCER THERAPY; CAULIFLOWER; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; HEP 2 CELL; HUMAN; HUMAN CELL; REVERTANT; SPECTROPHOTOMETRY;

BRASSICA OLERACEA VAR. BOTRYTIS; BRASSICACEAE;

EID: 0037000019     PISSN: 00315362     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. AKIYAMA S I, CHEN Z S, SUMIZAWA T, FURUKAWA T 1999 Resistance to cisplatin. Anti-Cancer Drug Design 14: 143-151
2. ARNAO M B, SANCHEZ-BRAVO J, ACOSTA M 1996 Indole-3-carbinol as a scavenger of free radicals Biochem Mol Biol Int 39: 1125-1134
3. BEKETIĆ-OREŠKOVIĆ L, OSMAK M 1994 Human larynx carcinoma cells resistant to cis-diammnedichloroplatinum(II) Cross-resistance pattern. Neoplasma 41: 171-176.
4. BJORKMAN R 1976 Properties and function of plant myrosinases; in Vaughan, MacLeod, Jones: The biology and chemistry of Cruciferae. Academic Press, London.
5. BRADFIELD C A, BJELDANES L F 1991 Modification of carcinogen metabolism by indolylic autolysis products of Brassica oleraceae. Adv Exp Med Biol 289: 153-163
6. BROCKMAN H E, STACK H F, WATERS M D 1992 Antimutagenicity profiles of some natural substances. Mut Res 267:157-172
7. CHRISTENSEN J G, LeBLANC G A 1996 Reversal of MDR in vivo by dietary administration of the phytochemical indole-3-carbinol. Cancer Res 56: 574-581
8. ENDICOTT J A, LING V 1989 The biochemistry of P-glycoproetin mediated drug resistance. Annu Rev Biochem 58: 137-171
9. HAMILTON T C, WINKER M A, LOUI K G, BATIST G, BEHRENS B, TSURUO T, GROTZINGER K R, McKOY W M, YOUNG R C, OZOLS R F 1985 Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity drug-resistant and sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochemical Pharmacology 34: 2583-2586
10. HRYCYNA C A 2001 Molecular genetic analysis and biochemical characterization of mammalian P-glycoproteins involved in multidrug resistance (Review). Seminars in Cell & Developmental. Biology (Semin Cell Dev Biol) 12: 247-256
11. INTERNATIONAL STANDARD 1992 Rapseed-determination of glucosinolates contents. Part I: Method using high-performance liquid chromatography. ISO 9167-1
12. KEARNS P R, HALL A G 1998 Glutathione and the response of malignant cells to chemotherapy. DDT 3: 113-121
13. KONIG J, NIES A T, CHI Y, LEIER I, KEPPLER D 1991 Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specifity, and MRP2-mediated drug resistance. Biochimica et Biophysisca Acta 1461:377-394
14. LAI G M, OZOLS R F, YOUNG R C, HAMILTON T C 1989 Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J Nation Can Inst 81: 535-539
15. LOCIGNO R, CASTRONOVO V 2001 Reduced glutathione system: Role in cancer development, prevention and treatment (Review). Int J Oncol 19: 221-236
16. MEISTER A 1994 Glutathione, ascorbate, and cellular protection. Cancer Research 54: 1969s-1975s.
17. MICKISCH G, S. FAJTA G, KEILHAUER E, SCHLIKE E, TSCHADA P, ALKEN P 1990 Chemosensitivity testing of primary human renal cell carcinoma by tetrazolium based microculture assay (MTT). Urological Research 18: 131-136
18. NIELSEN D, MAARE C, SKOVSGAARD T 1996 Cellular resistance to anthracyclines. General Pharmacology 27: 251-255
19. OSMAK M, BEKETIĆ-OREŠKOVIĆ L, MATULIĆ M, SORIĆ J 1993 Resistance of human larynx carcinoma cells to cisplatin, gamma irradiation and methotrexate does not involve overexpression of c-myc or c-Ki-ras oncogenes. Mutation Research 303: 113-120
20. OSMAK M 1998 Molecular alterations induced in drug-resistant cells. Radiology and Oncology 32: 19-33
21. PEHADŽIĆ J, DURGO K, RADE K, FRANEKIĆ J 1999 Antimutagenic effect of indole glucosinolates from Cruciferae family on 2-AA induced mutagenicity in prokaryotic test system. Period biol 101: 203-210
22. SANDSTROM P A, MANNIE M D, BUTTKE T M 1994 Inhibition of activation-induced death in T cell hybridomas by thiol antioxidants: oxidative stress as a modulator of apoptosis. J Leukem Biol 55: 221-226
23. SASAGAWA C, MATSUSHIMAT 1991 Mutagen formation on nitrite treatment of indole compounds derived from indole glucosinolate. Mut Res 250: 169-174
24. SCHMITT C A, LOWE S W 1999 Apoptosis and therapy. J Pathol 187: 127-137.
25. SCHMITT C A, LOWE S W 2001 Apoptosis is critical for drug response in vivo (Review). Drug Resistance Updates 4: 132-134
26. SHARMAS, STUTZMAN J D, KELLOFF GJ, STEELE V E 1994 Screening of potential chemopreventive agents using biochemical markers of carcinogenesis. Cancer Res 54: 5848-5855
27. SKATRUD P L 2002 The impact of multiple drug resistance (MDR) proteins on chemotherapy and drug discovery. In: Progress in Drug Research 58; Jucker E (ed). Birkhauser Verlag, Basel, Switzerland, p 101-137
28. SLATER A F G, STEFAN C, NOBEL I, VAN DEN DOBBEL-STEEN D J, ORRENIUS S 1995 Signaling mechanisms and oxidative stress in apoptosis. Toxicology Letters 82: 149-153
29. TIETZE F 1969 Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Analytical Biochemistry 27: 502-522.
30. VAN IERSEL M L P S, VERHAGEN H, VAN BLADEREN P J 1999 The role of biotransformation in dietary anticarcinogens. Mut Res 443: 259-270
31. ZHANG K, MACK P, WONG K P 1998 Glutathione-related mechanisms in cellular resistance to anticancer drugs (review). Internat J Oncol (skraćeni naziv)12: 871-882.